Non-Invasive Prenatal Testing Market Size, Share & Trends Analysis Report, By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Pregnancy Risk (High & Average Risk, Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests), By Technology, By Product, By Application, By End-User, By Region, Forecasts, 2024-2031

Report Id: 1425 Pages: 175 Last Updated: 03 July 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Non-Invasive Prenatal Testing Market

Non-Invasive Prenatal Testing Market- By Gestation Period

  • 0-12 Weeks
  • 13-24 Weeks
  • 25-36 Weeks

non-invasive prenatal testing

Non-Invasive Prenatal Testing Market- By Pregnancy Risk

  • High & Average Risk
  • Low Risk

Non-Invasive Prenatal Testing Market- By Method

  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-Free DNA in Maternal Plasma Tests

Non-Invasive Prenatal Testing Market- By Technology

  • NGS
  • Array Technology
  • PCR
  • Others

Non-Invasive Prenatal Testing Market- By Product

  • Consumables & Reagents
  • Instruments

Non-Invasive Prenatal Testing Market- By Application

  • Trisomy
  • Microdeletion Syndrome
  • Other Applications

Non-Invasive Prenatal Testing Market- By End-use

  • Hospitals & Clinics
  • Diagnostic Laboratories

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Non-Invasive Prenatal Testing Market Snapshot

Chapter 4. Global Non-Invasive Prenatal Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Gestation Period Estimates & Trend Analysis
5.1. by Gestation Period & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Gestation Period:
5.2.1. 0-12 Weeks
5.2.2. 13-24 Weeks
5.2.3. 25-36 Weeks

Chapter 6. Market Segmentation 2: by Pregnancy Risk Estimates & Trend Analysis
6.1. by Pregnancy Risk & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Pregnancy Risk:
6.2.1. High & Average Risk
6.2.2. Low Risk

Chapter 7. Market Segmentation 3: by Method Estimates & Trend Analysis
7.1. by Method & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Method:
7.2.1. Ultrasound Detection
7.2.2. Biochemical Screening Tests
7.2.3. Cell-Free DNA in Maternal Plasma Tests

Chapter 8. Market Segmentation 4: by Technology Estimates & Trend Analysis
8.1. by Technology & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
8.2.1. NGS
8.2.2. Array Technology
8.2.3. PCR
8.2.4. Others

Chapter 9. Market Segmentation 5: by Product Estimates & Trend Analysis
9.1. by Product & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
9.2.1. Consumables & Reagents
9.2.2. Instruments

Chapter 10. Market Segmentation 6: by Application Estimates & Trend Analysis

10.1. by Application & Market Share, 2019 & 2031
10.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
10.2.1. Trisomy
10.2.2. Microdeletion Syndrome
10.2.3. Other Applications

Chapter 11. Market Segmentation 7: by End-Use Estimates & Trend Analysis

11.1. by End-Use & Market Share, 2019 & 2031
11.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-Use:
11.2.1. Hospitals & Clinics
11.2.2. Diagnostic Laboratories

Chapter 12. Non-Invasive Prenatal Testing Market Segmentation 3: Regional Estimates & Trend Analysis

12.1. North America

12.1.1. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.1.2. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.1.3. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.1.4. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.1.5. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.1.6. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.1.7. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.1.8. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

12.2. Europe

12.2.1. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.2.2. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.2.3. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.2.4. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.2.5. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.2.6. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.2.7. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.2.8. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

12.3. Asia Pacific

12.3.1. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.3.2. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.3.3. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.3.4. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.3.5. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.3.6. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.3.7. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.3.8. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

12.4. Latin America

12.4.1. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.4.2. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.4.3. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.4.4. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.4.5. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.4.6. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.4.7. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.4.8. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

12.5. Middle East & Africa

12.5.1. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.5.2. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.5.3. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.5.4. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.5.5. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.5.6. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.5.7. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.5.8. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles

13.2.1. Genesis Genetics (CooperSurgical, Inc.)
13.2.2. Natera, Inc.
13.2.3. Eurofins LifeCodexx GmbH
13.2.4. Illumina, Inc. (Verinata Health, Inc.)
13.2.5. Centogene N.V.
13.2.6. MedGenome Labs Ltd.
13.2.7. Myriad Women’s Health, Inc. (Counsyl, Inc.)
13.2.8. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
13.2.9. Qiagen
13.2.10. Laboratory Corp. of America Holdings
13.2.11. Progenity, Inc.
13.2.12. Quest Diagnostics, Inc.
13.2.13. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
7896
Security Code field cannot be blank!

Frequently Asked Questions

The Non-Invasive Prenatal Testing Market Size is valued at USD 4.63 billion in 2023 and is predicted to reach USD 12.20 billion by the year 2031.

The Non-Invasive Prenatal Testing Market is expected to grow at a 13.02 % CAGR during the forecast period for 2024-2031.

Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Lab

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying